Results 111 to 120 of about 4,485 (189)

Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo [PDF]

, 2018
Current efforts toward human immunodeficiency virus (HIV) eradication include approaches to augment immune recognition and elimination of persistently infected cells following latency reversal.
Carolina Garrido, Natalia Soriano-Sarabia, Marina Tuyishime, Maria Abad-Fernandez, David M. Margolis, Justin J. Pollara, Guido Ferrari   +6 more
core   +1 more source

Noncanonical-NF-κB activation and DDX3 inhibition reduces the HIV-1 reservoir by elimination of latently infected cells ex-vivo

Microbiology Spectrum
Latency reversal and subsequent elimination of the human immunodeficiency virus-1 (HIV-1) reservoir using a combination of compounds with different mechanisms of action are considered a promising tool for HIV-1 cure.
Jade Jansen, Stefanie Kroeze, Shirley Man, Matteo Andreini, Jan-Willem Bakker, Claudio Zamperini, Alessia Tarditi, Neeltje A. Kootstra, Teunis B. H. Geijtenbeek   +8 more
doaj   +1 more source

Interleukin-2 is a potent latency reversal agent in people with treated HIV-1

Science Advances
Eliciting HIV-1 expression from latently infected CD4 + T cells allows these rare reservoir cells to become targets of the immune system and may also result in death of reservoir cells via virus-induced cytopathy.
Michael L. Freeman, Brian M. Clagett, Konstantin Leskov, Daniela Moisi, George A. Yendewa, Scott F. Sieg, Gregory M. Laird, Jonathan Karn, Jeffrey M. Jacobson, Benigno Rodriguez, Michael M. Lederman   +10 more
openaire   +3 more sources

Effective and targeted latency reversal in CD4⁺ T cells from individuals on long term combined antiretroviral therapy initiated during chronic HIV-1 infection [PDF]

To date, an affordable, effective treatment for an HIV-1 cure remains only a concept with most “latency reversal” agents (LRAs) lacking specificity for the latent HIV-1 reservoir and failing in early clinical trials.
Samiri Jamiru (18112371), Eric J. Arts (11846438), Tsigereda Biru (18112365), Jessica L. Prodger (9016712), Renata Ceccacci (18112362), Andrew D. Redd (6695216), Jamie F. S. Mann (16243997), Minh Ha Ngo (18112350), Ryan C. Y. Ho (18257394), Steven J. Reynolds (9176807), David H. Canaday (10431707), Paul Buule (18112377), Taddeo Kityamuweesi (18112374), Joshua Pankrac (18112353), Katja Klein (110677), Robert Assad (18112368), Aggrey Anok (9946237), Yue Li (102191), Thomas C. Quinn (6695213), Emmanuel Ndashimye (4591465), Rahul Pawa (18112359), Ronald M. Galiwango (9306104), Colin Kovacs (93789), Jeffrey M. Jacobson (10575533), Stephen Tomusange (17238265), Abayomi S. Olabode (12889292)   +25 more
core   +1 more source

The latest evidence for possible HIV-1 curative strategies [PDF]

, 2018
Human immunodeficiency virus type 1 (HIV-1) infection remains a major health issue worldwide. In developed countries, antiretroviral therapy has extended its reach from treatment of people living with HIV-1 to post-exposure prophylaxis, treatment as ...
Hanh Thi Pham, Thibault Mesplède
core   +1 more source

Enhancing HIV-1 latency reversal through regulating the elongating RNA Pol II pause-release by a small-molecule disruptor of PAF1C. [PDF]

Sci Adv, 2023
Soliman SHA, Cisneros WJ, Iwanaszko M, Aoi Y, Ganesan S, Walter M, Zeidner JM, Mishra RK, Kim EY, Wolinsky SM, Hultquist JF, Shilatifard A.   +11 more
europepmc   +1 more source

HIV-1 latency reversing agents converge on phosphoregulation of nuclear protein complexes

ABSTRACT Despite the success of antiretroviral therapy (ART), HIV-1 persists in latently infected cells, posing a central barrier to a cure. “Shock-and-kill” strategies using latency-reversing agents (LRAs) have shown some promise in reactivating viral gene expression ex vivo , but ...
Ni, Jocelyn J., Kaushal, Prashant, Sharma, Shipra, Makanani, Sara K., Delgado, Yennifer, Blanc, Sophie F., Olwal, Charles Ochieng, Ashley, Immy A., Winters, Declan M., Yang, Vivian, Phung, Callie N., Alba, Kareem, Wynn, Evan, Johnson, Jeffrey R., Hultquist, Judd F., Fregoso, Oliver I., Bouhaddou, Mehdi   +16 more
openaire   +2 more sources

Targeted bacteriophage T4 nanoparticles reverse HIV-1 latency in human T cell line models

iScience
Summary: A major barrier for HIV-1 eradication is the latent virus reservoir containing stably integrated and silent proviruses in CD4+ T cells. Targeted reactivation and removal of this latent reservoir is a potential strategy for HIV-1 cure, but ...
Himanshu Batra, Jingen Zhu, Swati Jain, Neeti Ananthaswamy, Marthandan Mahalingam, Pan Tao, Camille Lange, Shawn Hill, Chaojie Zhong, Mary F. Kearney, Haitao Hu, Frank Maldarelli, Venigalla B. Rao   +12 more
doaj   +1 more source

Ethnopharmacological exploration and isolation of HIV-1 latency-reversing agents from Sudanese medicinal plants

Frontiers in Pharmacology
HIV-1 infection remains a major health challenge, especially in resource-limited settings such as Sudan, where traditional medicine is widely practiced for managing infectious diseases, including HIV/AIDS.
Khaled M. Elamin, Naoki Kishimoto, Naoki Kishimoto, Teppei Kawahara, Sara Mustafa Idris Elbashir, Tae Yasutake, Mikiyo Wada, Yuki Hitora, Maha Kordofani, Wadah Osman, Wadah Osman, Mustafa Idris Elbashir, Shogo Misumi, Shogo Misumi   +13 more
doaj   +1 more source

Evaluation of HIV-1 latency reversal and antibody-dependent viral clearance by quantification of singly spliced HIV-1 vpu/env mRNA. [PDF]

J Virol, 2021
Gao H, Ozantürk AN, Wang Q, Harlan GH, Schmitz AJ, Presti RM, Deng K, Shan L.   +7 more
europepmc   +1 more source